RxSight, Inc. (RXST): Price and Financial Metrics
RXST Price/Volume Stats
| Current price | $54.54 | 52-week high | $66.54 |
| Prev. close | $53.46 | 52-week low | $20.66 |
| Day low | $53.05 | Volume | 608,200 |
| Day high | $55.29 | Avg. volume | 483,853 |
| 50-day MA | $50.88 | Dividend yield | N/A |
| 200-day MA | $50.45 | Market Cap | 2.02B |
RXST Stock Price Chart Interactive Chart >
RxSight, Inc. (RXST) Company Bio
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest RXST News From Around the Web
Below are the latest news stories about RXSIGHT INC that investors may wish to consider to help them evaluate RXST as an investment opportunity.
RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving AverageGood things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react? |
RxSight, Inc. (NASDAQ:RXST) Q3 2023 Earnings Call TranscriptRxSight, Inc. (NASDAQ:RXST) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good day, and thank you for standing by. Welcome to the RxSight Third Quarter 2023 Earnings Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex […] |
Here's Why We're Not Too Worried About RxSight's (NASDAQ:RXST) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Q3 2023 Rxsight Inc Earnings CallQ3 2023 Rxsight Inc Earnings Call |
RxSight, Inc. Reports Third Quarter 2023 Financial ResultsALISO VIEJO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: The sale of 66 Light Delivery Devices (LDD™s |
RXST Price Returns
| 1-mo | 4.56% |
| 3-mo | -8.09% |
| 6-mo | 15.58% |
| 1-year | 96.97% |
| 3-year | 306.41% |
| 5-year | N/A |
| YTD | 35.27% |
| 2023 | 218.23% |
| 2022 | 12.62% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...